Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives
- PMID: 3668249
Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives
Erratum in
- J Hypertens 1987 Dec;5(6):following H54
Abstract
The aim of the present study was to monitor the efficacy of treatment, morbidity and mortality over a 10-year period in 939 moderate to severe hypertensive patients. All patients were treated in the same hypertension clinic with the beta 1-selective agent atenolol, administered either alone or more usually with a diuretic with or without a vasodilator or other agents. Survival rates were compared with predicted survival rates, had the hypertension not been treated, and also with those of a local reference population matched for age and sex. After a mean follow-up time of 6.1 years, mean blood pressure (BP) was significantly lowered from 183/109 to 145/87 mmHg. Biochemical disturbance was minimal. There were 79 withdrawals from treatment, of whom 37 were lost to follow-up. There were 91 deaths on intention to treat. Systolic blood pressure (SBP) on treatment, and not initial BP, was a powerful predictor of mortality. Patients of all age groups with well-controlled SBP were less likely to die, particularly from myocardial infarction, than those with less well controlled SBP (P less than 0.001). However, due to possible J-curve relationships between treated BP and outcome, lowering SBP below 140-150 mmHg in the elderly, and the diastolic blood pressure (DBP) below about 85 mmHg, may not be beneficial. Total mortality and mortality due to myocardial infarction was about 60% [corrected], of predicted level, had a high BP not been treated, being similar to that in a local reference control population (age- and sex-matched). The death rate from stroke was reduced to about 50% of that predicted. Patients who died showed a mean fall in mean serum triglyceride concentration in contrast to the mean increase that occurred in survivors. It is concluded that patients with moderate to severe hypertension who obtain a high level of general health care and optimal control of BP for up to 10 years, experience a significant decrease in total mortality rate and death from myocardial infarction and stroke.
Similar articles
-
Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol).Drugs Exp Clin Res. 1990;16(3):133-6. Drugs Exp Clin Res. 1990. PMID: 2387213
-
The efficacy and tolerability of antihypertensive treatment based on atenolol in the prevention of stroke and the regression of left ventricular hypertrophy.J Hum Hypertens. 1987 Sep;1(2):87-93. J Hum Hypertens. 1987. PMID: 3506623
-
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.Clin Ther. 2005 May;27(5):578-87. doi: 10.1016/j.clinthera.2005.05.006. Clin Ther. 2005. PMID: 15978306 Clinical Trial.
-
Isolated systolic hypertension in the elderly: lessons from clinical trials and future directions.J Hypertens Suppl. 1999 Dec;17(5):S49-54. J Hypertens Suppl. 1999. PMID: 10706327 Review.
-
Why has the primary prevention of myocardial infarction in the treatment of hypertension been so elusive?J Hum Hypertens. 1987 Sep;1(2):73-81. J Hum Hypertens. 1987. PMID: 3333527 Review.
Cited by
-
Hypertension in the elderly.Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 5:947-50. doi: 10.1007/BF02018298. Cardiovasc Drugs Ther. 1990. PMID: 2076405 Review.
-
Beta blockers and carbohydrate and lipoprotein metabolism in hypertensive patients.BMJ. 1989 Jun 10;298(6687):1581-2. doi: 10.1136/bmj.298.6687.1581-c. BMJ. 1989. PMID: 2569336 Free PMC article. No abstract available.
-
The beta blockers: are they as protective in hypertension as in other cardiovascular conditions?J Clin Hypertens (Greenwich). 2001 Jul-Aug;3(4):236-43. doi: 10.1111/j.1524-6175.2001.00444.x. J Clin Hypertens (Greenwich). 2001. PMID: 11498654 Free PMC article. Review.
-
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.Drugs. 1991 Sep;42(3):468-510. doi: 10.2165/00003495-199142030-00007. Drugs. 1991. PMID: 1720383 Review.
-
Beta blockers, lipids, and coronary atherosclerosis: fact or fiction?Br Med J (Clin Res Ed). 1988 Mar 12;296(6624):731-2. doi: 10.1136/bmj.296.6624.731. Br Med J (Clin Res Ed). 1988. PMID: 2894885 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical